The "Global Cryptococcosis Treatment Market 2020-2025" report has been added to ResearchAndMarkets.com's offering.
The Global Cryptococcosis Treatment Market is estimated to be USD 4.6 Bn in 2020 and is expected to reach USD 5.7 Bn by 2025 growing at CAGR of 4.5%.
Certain infections like HIV which lead to a weak immune system as well as the extended use of immunosuppressive drugs are supporting the growth of this market. Alternatively, lack of efficient diagnostic tools and trials to prevent this infection are digressing the growth of this market.
Cryptococcosis or cryptococcal disease is basically a fungal disease, which can prove to be fatal in severe cases. It occurs due to inhalation of fungus associated with bird species. It can affect the humans leading to meningitis in several cases. The occurrence of this disease is increasing beyond years due to the rise in the number of diseases especially prevalent in the emerging economies.
The growing incidence of cryptococcosis infections
Increasing incidence of fatal fungal infections
Increasing availability of generic and over-the-counter (OTC) medicines
Reduced scope of testing and diagnostics due to increased mortality among cryptococcosis infected patients
Limited clinical awareness in patients
Lack of skilled technicians
Drug development and evolving clinical trial ecosystem
Initiatives undertaken by the government, NGOs, and the healthcare providers
The Global Cryptococcossis market can be segmented on the basis of treatment, distribution channel and geography. By Geography, North America leads the market.
Global Cryptococcosis Treatment Market, By Treatment
Others (Voriconazole, Surgery Treatment, etc.)
Global Cryptococcosis Treatment Market, By Distribution Channel
Mail Order Pharmacies
Retail Pharmacies & Drug Stores
Global Cryptococcosis Treatment Market, By Geography
Middle East and Africa
Some of the companies covered in this report are Glenmark Pharmaceuticals, Abbott Laboratories, Pfizer, Bristol-Mayers Squibb, Sigmapharm Laboratories, Novartis AG etc.
IGR Competitive Quadrant
The report includes IGR Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share etc.
Why buy this report?
The report offers a comprehensive evaluation of the Global Cryptococcosis Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys and observation of renowned personnel in the industry.
The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of COVID-19 on the market is also featured in the report.
The report also contains the competitive analysis using IGR Positioning Quadrants, the publisher's proprietary competitive positioning tool.
A complete analysis of the market including parent industry
Important market dynamics and trends
Historical, current, and projected size of the market based on value and volume
Market shares and strategies of key players
Recommendations to companies for strengthening their foothold in the market
Bristol-Myers Squibb Company
Janssen Biotech, Inc. (Johnson & Johnson)
Valeant Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc.
Sigmapharm Laboratories LLC
Astellas Pharma Inc.
Bausch Health Companies Inc.
NuCare Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/ghuvdz
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005549/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900